Ab-drug conjugates have been approved by the FDA for treatment of Hodgkin lymphoma [22], HER2-positive breast cancer [23], acute myeloid leukaemia [24], and lymphoblastic leukaemia [25]; many others are currently in clinical trials for various diseases [26]. Here, ERBB2 is linked to breast carcinoma.